RS
CPRX

R Squared’s Catalyst Pharmaceutical CPRX Stock Holding History

R Squared’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
+13,228
New +$390K 0.22% 137

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's CPRX Position: Q2 2026 in Review

R Squared opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 13,228 shares worth $416K. The stake represents 0.22% of the portfolio and ranks #137 among its holdings.

395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • R Squared held 13,228 shares of Catalyst Pharmaceutical worth $416K as of Q2 2026.
  • Catalyst Pharmaceutical was a new R Squared position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.22% of R Squared's portfolio in Q2 2026, its #137 holding.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.